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ABSTRACT 
 Myotonic dystrophy is a debilitating genetic disorder which currently does not have a 
therapeutic treatment.  It is understood that CTG expansions lead to formation of stable 
poly(CUG) mRNA which mislocalize splicing factors such as MBNL1 and lead to missplicing in 
the cell.  One therapeutic strategy is to target such mutant mRNA with small molecules to 
prevent the sequestration of splicing factors which will prevent the multiple missplicing events in 
the cell and reverse the symptoms of the disorder.  In the following thesis I describe my work in 
identifying small molecule inhibitors of the RNA-protein complex through the optimization of 
gel shift assays for characterization of rationally-designed compounds and the development of a 
fluorescence anisotropy assay for a high-throughput screening of the NCI Diversity Set III 
compound library.  From such studies I was able to identify several lead compounds that are 
successful at inhibiting the pathological nuclear aggregation.   
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CHAPTER 1 
MYOTONIC DYSTROPHY AND THE THERAPEUTIC POTENTIAL OF 
SMALL MOLECULES 
 
1.1 Overview of Myotonic Dystrophy 
 Myotonic dystrophy (DM) is a complex genetic disorder with multiple effects across 
various organ systems.
1
  It is the second most common form of muscular dystrophy affecting 1 in 
8,000 people worldwide.
2
  Features of the disorder include myotonia, muscle wasting, insulin 
resistance, cardiac conduction defects, cataracts, and cognitive dysfunction.
3
 There are two forms 
of DM based on the location and type of nucleotide expansion.  DM1 is the result of CTG repeat 
expansions in the 3’-UTR of the DMPK (dystrophia myotonica protein kinase) gene, whereas 
DM2 resulted from a tetranucleotide CCTG repeat expansion in intron 1 of the ZNF9 (zinc-
finger 9) gene.
4
  The genomic instability is hereditary and the length of the repeated region 
positively correlates with the severity of the disorder.
5
  For DM1, repeat lengths greater than 50 
results in the development of symptoms of the disorder.
6  
Because of such genetic factors, 
offspring of DM patients experience earlier onset and more severe symptoms.  
 An RNA gain-of-function model has been proposed to explain the pathogenesis of DM 
(Figure 1).  Upon transcription of expanded poly(CTG) DNA (Fig. 1a), the nascent poly(CUG) 
RNA folds into a stable secondary structure that aggregates in the nucleus (Fig. 1b); altering 
cellular levels of DMPK as well as affecting nuclear mRNA transport.
7-9
  More importantly, the 
poly(CUG) aggregate interacts with various splicing factors, resulting in mislocalization and 
missplicing of multiple proteins. (Fig. 1c)
10-12
  Misspliced proteins result in the multisystemic 
symptoms of DM.
13
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Figure 1.  Schematic of RNA gain-of-function model for pathogenesis of myotonic dystrophy 
 
1.2 Trinucleotide Repeat Expansions 
 The CTG repeats observed in myotonic dystrophy belong to a family of short tandem 
repeats known as trinucleotide repeats (TNR).  Short tandem repeats are quite common in the 
human genome and constitute 30% of the total DNA.
14,15  
Of such sequences, trinucleotide 
repeats are the most tolerated length of repeats because they do not shift the open-reading frame 
for protein translation.  A survey of the human genome revealed the presence of greater than 
32,000 tracts of six or more trinucleotide repeats.
16  
Currently there is limited understanding of 
the function of such repeats but research suggests trinucleotide repeats exist to regulate 
transcription and translation as expansion leads to various neurological and muscular 
degenerative disorders.
17
   For example, CGG expansion is observed in Fragile X syndrome, 
CAG expansion is observed in Huntington's disease and 8 other disorders, GAA expansion is 
observed in Friedreich's Ataxia, GCG expansions is observed in oculopharyngeal muscular 
dystrophy, and CTG expansion is observed in DM. (Figure 2)
18-20  
Although the above mentioned 
disorders all result from expansion of DNA, the location of the expansion alters disease 
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pathogenesis.  For those expansion in the exon such as Huntington's disease; the pathogenesis is 
much more direct.  Translation of expanded mRNA leads to defective protein with expanded 
amino acids and leads to loss of protein function.   For those expansions that occur in the intron 
or the untranslated region such as myotonic dystrophy, pathogenesis is often more complex.     
 
Figure 2.  Examples of trinucleotide expansions and the associated genetic disorder 
 
1.3 Mutant DMPK mRNA and MBNL1 
 As previously mentioned, the poly(CTG) expansions occur in the 3' untranslated region 
of the DMPK gene, thus early studies were focused on understanding the effects of such 
expansion.  In 1995, Singer and coworkers utilized a fluorophore-tagged CAG10 antisense 
oligonucleotide to visualize the location of the poly(CUG) transcript.  They reported that the 
concentration of poly(CUG) transcripts were much higher in DM fibroblasts than normal 
fibroblasts whereas in the cytoplasm the concentration is the same.
21  
.  Several years later, a 
second paper by the group reported that DM myoblasts also had such nuclear foci.  They 
proposed that mutant DMPK mRNA aggregated into nuclear foci to prevent self-export and the 
export of other mRNAs, leading to disruption of protein synthesis.
22   
Reduction in mRNA 
transport would lead to decreased protein production and potentially DM symptoms.  Reddy and 
coworkers investigated this with mouse models deficient in DMPK.  They reported that DMPK  
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(-/-) mice developed late-onset, progressive skeletal myopathy that share some pathological 
features with DM.  They suggest DMPK may be necessary for the maintenance of skeletal 
muscles but loss of DMPK is not the major cause of DM symptoms.
23 
 This agrees with the 
observation that the severity of the symptoms correlates with expansion length.  If nuclear 
aggregation leads to DM, then expansion length should not correlate with severity once the 
threshold expansion size has been reached.   
 
Further studies focused on analyzing the composition of the nuclear aggregates to 
discover the cause of DM symptoms.  A critical observation was made by Thornton and 
coworkers concerning the presence of various RNA-binding proteins in the nuclear aggregates; 
including those in the muscle-blind and CUG-BP family of alternative splicing factors.
24  
From 
such observations they hypothesized that mislocalization of alternative splicing factors may be 
the main cause for DM.  In support for such hypothesis, experiments with transgenic mice and 
fly models both demonstrate that mislocalization of RNA-binding proteins more readily 
reproduced the symptoms of DM.
25,26
  In the drosophila model, Botas and coworkers found that 
by expressing a non-coding mRNA containing 480 CUG repeats they were able to recreate DM 
symptoms in the flies.  To identify which RNA-binding protein is the most essential, they 
transfected the DM flies with both MBNL1 and CUGBP1 plasmid and altered the expression 
level of each protein.  It was observed that increased levels of MBNL1 alleviated the RNA-
induced toxicity whereas altered levels of CUGBP1 had lesser effects.
25  
Mouse models were 
also studied to confirm the hypothesis.  MBNL1 knockout mice (MBNL1
ΔE3/ ΔE3
) were observed 
by Swanson to manifest the majority of myotonic dystrophy symptoms.
27
  Overexpression of 
MBNL1 in DM mouse models was again found to alleviate the disorder.
28
  The combination of 
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these results suggested that MBNL1 mislocalization is the main cause for DM and that 
restoration of native MBNL1 leads to rescue of disease symptoms. 
 Realizing that MBNL1 is an important protein in the pathogenesis of myotonic dystrophy, 
multiple research groups focused on understanding its native target and protein structure.  
Berglund and coworkers published a study in 2007 detailing a comparison between the native 
substrate of MBNL1 and the secondary structure formed by poly(CUG) repeats.
29  
Electrophoretic mobility shift assay (EMSA) was performed to determine the Kd of MBNL1 
binding with various lengths of CUG and CCUG repeat constructs, pyrimidine mismatches, and 
native intronic targets such as cardiac troponin T.  Analysis of the results revealed that MBNL1 
preferentially binds pyrimidine mismatches, U-U and C-C, with a nanomolar Kd similar to that of 
the intronic target.  Circular dichroism studies and thermal melting data suggests MBNL1 
binding requires the bulged stem-loop structure.
30
  MBNL1 did not bind true double stranded 
RNA such as that formed by CUG and CAG.
30  
Using a stem-loop RNA construct with a 
fluorophore at the 5' and a quencher at the 3', Baranger and coworkers observed that upon 
addition of MBNL1 fluorescence quenching was eliminated.  The increase in fluorescence signal 
suggests that the stem-loop broke apart as a result of MBNL1 binding.
31
  A secondary 
experiment to confirm the observation was done by measuring the binding affinity of MBNL1 to 
stem-loop RNA with increasing amounts of stem stability.  MBNL1 had highest affinity for 
RNA with weak stem stability and lowest affinity for RNA with strong stability.  These findings 
confirm the importance of bulged stem-loop RNA for MBNL1 binding.  A crystal structure of 
poly(CUG) RNA revealed that it is similar to A-form duplex RNA with a right-handed helical 
pattern containing bulges at U-U mismatches.
32  
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1.4 Potential Therapeutic Approaches 
 From the RNA gain-of-function model, poly(CTG) DNA is transcribed into mutant 
DMPK mRNA which forms nuclear foci that mislocalize MBNL1 leading to the symptoms of 
DM.  There are three levels where therapeutic intervention have been suggested to treat the 
disorder; the DNA level, the RNA level, and the protein level.
33  
At the DNA level, one would 
need to prevent the CTG expansion as well as to contract already expanded CTG tracts.  Progress 
has been limited by the availability of specific DNA binders capable of inducing DNA 
contraction in non-dividing cells.  In a proof-of-concept experiment, Sinden and coworkers have 
shown that treating DM1 lymphoblast cells with chemotherapeutic agents such as mitomycin C, 
mitoxantrone, and doxorubicin can lead to CTG repeat contraction.
34
  However, such compounds 
are known to be nonspecific DNA alkylating and intercalating agents with dose-limiting toxicity. 
Further development to improve selectivity are required if they are to be used in therapy.  
Antisense oligonucleotides have also been used to stabilize the expansion, but contraction of the 
expanded DNA with antisense oligonucleotides was not possible.
35  
At the protein level, it has 
been suggested that one can restore the concentrations of RNA-binding proteins.  However, that 
is a difficult task given the protein expression must be tissue selective and carefully controlled.  
Thus, most research groups have chosen to bypass the DNA and protein level and focus on the 
RNA level, working to disrupt the formation of the mRNA secondary structure and or preventing 
MBNL mislocalization.
36,37 
 
Multiple approaches to target the poly(CUG) repeats have been attempted, including the 
use of peptides
38
, antisense oligonucleotides, and small molecules.  With a morpholino 
poly(CAG)25 antisense oligonucleotide Wheeler and coworkers were able to displace 
mislocalized MBNL1.
39  
The oligonucleotide was designed to directly target the CUG repeats 
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and upon intravenous injection into DM mouse, it rescued the splicing abnormalities associated 
with the disorder.  A more recent example is published by Thornton and coworkers who 
targeted
40
 the intron of the mutant mRNA instead of the poly(CUG) tract.  The mechanism of 
action is believed to result from mRNA silencing through the RNase H-dependent mechanism.   
The silencing pathway increases the efficiency of the antisense oligonucleotide compared to 
direct binding to mutant mRNA; less is required to obtain the effect of degrading mutant mRNA 
nuclear foci. Although these examples demonstrate promise, both peptides and oligonucleotides 
suffer from the problem of enzymatic degradation, decreased membrane penetration, and poor 
nuclear retention.  Often intravenous injection is required for compound uptake.  Because of such 
limitations, small molecules may be better candidates to target the poly(CUG) RNA due to their 
smaller size for drug delivery and more established pharmacological properties.   
 
1.5 Published small molecule inhibitors of poly(CUG)-MBNL1 complex  
 The multiple U-U mismatches in poly(CUG) stem-loop provide binding sites for small 
molecules due to their rigidity, presence of multiple hydrogen donors and acceptors, and their 
repeated nature.
41  
One of the first small molecule inhibitor published is pentamidine by Berglund 
and coworkers. (Figure 3)
42  
Pentamidine was identified from a screen of twenty-six known 
nucleic acid binders using gel shift assay.  The molecule competed with MBNL1 and disrupted 
the poly(CUG)-MBNL1 complex with a IC50 of 58 µM.  In splicing assays, pentamidine was 
able to partially rescue the missplicing for insulin receptor and cardiac troponin T mRNA.  
Though promising, pentamidine is dose-limited by high cellular toxicity.  There are also 
concerns that correction of missplicing may result from off-target effects because pentamidine is 
known to be a non-selective nucleic acid binder.   
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Figure 3.  Pentamidine by Berglund and coworkers 
  
To improve selectivity and binding affinity, Disney and coworkers designed a oligomeric 
molecule based on monomers of a known nucleic acid dye, Hoechst 33258. (Figure 4)
43,44
  Each 
monomer subunit has only weak affinity to the U-U mismatched RNA, but upon optimization of 
the linker length and conjugating multiple subunits, a pentameric molecule allowed Disney and 
coworkers to achieve strong binding; IC50  of 28 nM.  The polymer also improved target 
selectivity by binding to RNA with consecutive U-U bulges.  Such results demonstrate the 
potential of increasing target specificity and affinity through combination of modular 
components.  However, the drawback of the polymer approach is the large increase in molecular 
weight of the compound which affects cellular and nuclear uptake.     
 
Figure 4.  Pentamer of Hoechst33258 (R) by Disney and coworkers 
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Our own group focused on targeting the RNA with molecules that can hydrogen bond to 
the U-U bulge.  In 2009, we reported on a triaminotriazine-acridine conjugate capable of 
displacing MBNL1 with an IC50 of 46 µM.
45
  The design resulted from careful study of the 
poly(CUG) crystal structure published by Mooers and coworkers
32
 which detailed the hydrogen 
bonding pattern of the U-U mismatch.  We reasoned that triaminotriazine can bind between the 
uracil bases with each face of the molecule fully complementing the hydrogen bonding patterns 
of the uracil, providing target selectivity. (Figure 5)  The conjugated acridine intercalates 
between RNA bases to afford increased binding affinity as well as stabilize the stem-loop 
structure which is important in prevent MBNL1 binding.  A combination of gel shift assays, 
isothermal calorimetry measurements, and computer modeling was performed to confirm the 
proposed binding mode.
46 
  
 
Figure 5. Compounds by Zimmerman and coworkers 
  
1.6 Summary 
 Myotonic dystrophy is a debilitating genetic disorder with no treatment options.  Studies 
on the pathogenesis of the disorder have found that an RNA gain-of-function is the cause for the 
disorder.  The stable secondary structure formed by the poly(CUG) RNA mislocalizes splicing 
regulator proteins in the nucleus.  Multiple studies suggest MBNL1 is the key splicing regulator 
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involved in myotonic dystrophy and overexpression of MBNL1 in animal models have reversed 
the symptoms of DM.  As a result, multiple methods were developed to prevent mislocalization 
of MBNL1.  Such methods include the use of synthetic peptides, antisense oligonucleotides, and 
small molecule inhibitors.  Although these methods have shown promise in reversing the 
symptoms of DM, additional research is necessary to develop them into potential therapeutics. 
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CHAPTER 2 
Screening and Identification of Lead Compounds from Rational Design and 
In Silico Screening 
 
2.1 Introduction 
 As discussed in the previous chapter, a potential treatment for myotonic dystrophy would 
be the displacement of mislocalized MBNL from the toxic poly(CUG) repeats with small 
molecules.  To be therapeutically relevant, such small molecules must be selective for the 
poly(CUG) RNA, bind the RNA with high affinity, and be cell and nucleus permeable.  Research 
in the group has taken two approaches to discover and identify such molecules; rational design 
by targeting the U-U mismatch with the triaminotriazine motif and an in silico pharmacophore-
based screen of 170,000 compounds from several small molecule libraries.  In the following 
chapter I detail my work in 1) optimization of electrophoretic mobility shift assay (EMSA) as a 
method to identify RNA binders, 2) identification of lead compounds from rational design 
approach, and 3) selection of hit molecules from in silico screens.     
 
2.2 Results and Discussion 
Optimization of EMSA for Identification of Small Molecule RNA Binders 
 The electrophoretic mobility shift assay, also known as EMSA or gel shift assay, was 
initially developed in 1981 by Garner and Revzin for studying the binding between DNA and 
protein components of the lactose operon system.
1
 Swanson and coworkers employed EMSA to 
analyze the interactions between MBNL1 and both its target pre-mRNA and also toxic 
poly(CUG) repeats.
2
  It is important to note that Swanson utilized a truncated MBNL1N which 
binds poly(CUG) constructs with binding constants similar to full length MBNL1 yet is much 
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easier to express using E. coli competent cells.
2
 This isoform of MBNL1 is used in our assay 
along with designed CUG4 and CUG12 stem-loop constructs. (Figure 6)  The RNA constructs are 
radiolabeled with 
32
P and the proportion of bound and free RNA can be visualized according to 
their rate of migration in the polyacrylamide gel.  The proportion of free RNA allows the 
quantification of  IC50 and Kd. 
 
Figure 6. Structure of poly(CUG) construct (a) CUG4 (b) CUG12 
 
The presence of a super-shifted aggregation band above the protein-RNA complex 
complicated interpretation of gel shift data, thus initial work focused on its removal.  Because the 
band was first observed for sample lanes with concentrated protein, it was believed to result from 
MBNL1N self-aggregation.  To reduce self-aggregation, the pH of the assay running buffer was 
decreased from 8.6 to 8.2, which is below the estimated isoelectric point of MBNL1N at 8.3.  A 
positive charge on the protein was believed to reduce protein self-aggregation by initiating 
binding to negatively charged RNA.  CUG4 and CUG12 annealing procedures were also changed 
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with the goal of favoring the formation of stem-loop RNA over duplex RNA.  Fast folding 
procedures of heat shocking at 90 °C for five minutes followed by five minutes on ice were 
changed to slow folding procedures where the RNA is placed in 90 °C water and slowly cooled 
over 90 minutes to room temperature.  The combination of these changes along with the addition 
of glycerol in the gel matrix to affect pore size greatly reduced the presence of aggregation bands.  
(Figure 7) 
 
 
The aggregation band was reduced but not completely removed until the discovery and 
removal of a protein contaminant in MBNL1N stock solution.  It was observed that MBNL1N 
expressed and purified at different times demonstrated varying amounts of the aggregation band 
in the gel shift assay.  Also, SDS-PAGE performed with MBNL1N revealed two additional 
bands upon Coomassie staining. (Figure 8)  The two bands are above and below the expected 
band for MBNL1N with molecular weights of 69 kDa and 26.9 kDa, confirmed by MALDI mass 
spectrometry. (Figure 9)  The contaminant bands were overlooked previously because they were 
only visible in SDS-PAGE experiments with the use of concentrated protein sample.  
Incorporating an additional column chromatography step with anionic exchange resin, the 
contaminants were separated from the protein.  Having isolated the contaminants, an equilibrium 
a                                                                                         b 
     
Figure 7. Small molecule inhibition assay to test effect of fast and slow folding with arrow pointing to 
supershifted band.  (a) fast folding  (b) slow folding 
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binding assay was performed to better understand how they could co-purify with MBNL1N.  It 
was discovered that these contaminants had measureable binding affinity for (CUG)12. (Figure 
10)  The current belief is that the 26.9 kDa band represents a miscleaved GST tag and the 69 kDa 
contaminant is an MBNL1 isoform because it has a ten-fold weaker binding to CUG12.  The lack 
of aggregation bands in the equilibrium binding assay with the contaminant and MBNL1N 
suggests that the aggregation originally observed resulted from the mixture of two protein 
species and was not from assay conditions. 
 
 
 
 
Figure 8. Coomassie stained SDS-PAGE gel. 
(L1) protein ladder (L2) purified MBNL1N (L3) contaminants 
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Figure 9.  MALDI-MS of isolated impurity (top) and MBNL1N (bottom) 
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Figure 10.  Equilibrium binding assay with (top) Contaminant Kd of 237 nM and (bottom) MBNL1N Kd of 26.6 nM 
 
 
After removing the supershifted aggregation bands, the next focus was on increasing the 
accuracy of the assay.  As explained by Shoichet and coworkers, screening assays are susceptible 
to identifying false positives resulting from aggregation-based inhibition.
3-5
  Some small 
molecules can exhibit noncompetitive inhibition through the formation of aggregates that prevent 
the MBNL1 from binding the RNA.  The use of detergent molecules such as Triton-X or Tween-
20 has been suggested to minimize aggregation-based inhibition.  To determine the adequate 
amount of Triton-X to incorporate, a sample screening assay was performed with known 
inhibitors and potential inhibitors at different concentrations of Triton-X.  The choice of 
incorporating 0.05% Triton-X in the sample buffer was made based on suggestions from the 
literature and the observation that this concentration of Triton-X did not alter the inhibitory 
profiles of the positive control compound.  From these studies it was observed that high amounts 
of Triton-X appear to increase the strength of MBNL1-CUG binding.    
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Identification of Lead Compounds from Rational Design 
  
 The approach to inhibiting CUG-MBNL binding through rational design of a U-U 
selective ligands was first reported by Arambula, who used the Janus binding motif of 
triaminotriazine to target U-U mismatches.
6
 Janus wedges are molecules that have two faces 
available for hydrogen bonding.
7
  The combination of triaminotriazine for selectivity and the 
intercalator acridine for increased nucleic acid binding affinity led to the development of ligand 1. 
A series of derivatives has since been synthesized by Wong, a current graduate student in the 
group, along with second-generation compounds of his own design. (Figure 11)   
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Ligand 1 by Arambula Ligand 2 Ligand 3 
 
 
 
 
 
 
Ligand 4 Ligand 5 Ligand 6 
 
 
 
 
 
 
Ligand 7 Ligand 8 Ligand 9 
 
 
 
 
 
Ligand 10 Ligand 11  
 
Ligand 12 
 
Figure 11.  Summary of triaminotriazine-acridine ligands. All ligands synthesized by Wong unless otherwise noted 
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 After the optimization studies, gel shift assays were used to evaluate the inhibitory effects 
of rationally-designed compounds. (Figure 12)  Ligand 1 is the best characterized compound so 
it was used as a positive control throughout the majority of EMSA experiments.  The other lanes 
contain derivatives of ligand 1 with methylations in different positions of the melamine for 
binding mode studies and substituent on the acridine to improve aqueous solubility.  A high ratio 
of MBNL1N to CUG12 was utilized to ensure 85% association in the control lane without small 
molecules.  Such stringent condition ensures that only the strongest inhibitors are selected from 
the assay.  From trials performed at 100 µM of small molecule, it was observed that ligand 1 had 
the best inhibitory activity and the derivatives did not greatly improve the inhibition.  Attempts 
to perform the experiment at higher small molecule concentrations failed due to small molecule-
based aggregation in the lanes.  Improving aqueous solubility became a major goal for the 
second generation of triaminotriazine-based ligands.  Although inhibition screening experiments 
did not identify a better derivative, the experimental data gave insight into the binding mode of 
triaminotriazine-acridine conjugates with U-U mismatches.
8  
Ligand 4 contains a single 
methylation of the amino group and it is the only one of the six methylated derivatives that 
retains inhibitory activity.  This suggests that the proposed Janus wedge binding motif is correct 
for small molecule binding to RNA as additional methylations on the amine groups prevent the 
hydrogen bonding and eliminates inhibitory effect.   
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Figure 12.  Representative result from a screening experiment. 
(Top) Image of screening gel (Bottom) Densitometry of screening experiment 
 
 In addition to screening experiments, gel shift assays were utilized to quantify the IC50 of 
the designed compounds.  Assuming the designed small molecules behaved as competitive 
inhibitors, the Cheng-Prusoff equation was used to estimate the Ki for a given compound based 
on measured IC50 and Kd . The Ki is a better measure of a compound's inhibitory effects since it 
takes into account the strength of the protein-RNA interaction.
9
 Because of the high small 
molecule concentration required for the full displacement of CUG12, reliable IC50 and Ki values 
of ligand 1 derivatives were not obtained.  Small molecule-based aggregation occurred in dose-
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dependent studies as a result of the compounds' poor aqueous solubility and this prevented it 
from entering the gel matrix.  The second generation compound, ligand 12, has much better 
aqueous solubility and its IC50 and Ki values have been measured with the gel shift assay. (Figure 
13)  The low micromolar IC50, 6.7 µM, translates to a Ki of 103 nM which is comparable to the 
most potent published small molecule inhibitor at 76 ± 15 nM.
10,11  
Fluorescence microscopy 
results visualize the displacement of MBNL from poly(CUG) foci in vivo, which provides 
support for the validity of the gel shift assay as a method to determine inhibitory activity.   
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Figure 13.  Representative result from dose-dependent experiment 
(Top) Representative gel image (Bottom) Densitometry data 
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Identification of Lead Compounds from in silico Pharmacophore Screening 
 A screening approach was used to identify small molecules that can target the minor 
groove of the poly(CUG) RNA.  A postdoctoral fellow in the lab, Tiziano Tuccinardi, designed 
an in silico glycerol-based pharmacophore screen of 170,000 small molecules from the 
Chembridge, Marvel, NCI, and high-throughput screening facility at the University of Illinois 
compound libraries.  The glycerol pharmacophore was chosen because the crystal structure 
submitted by Krzyzosiak and coworkers (PDB ID: 3GLP) contained a glycerol interacting with 
the minor groove of poly(CUG)4. (Figure 14)
12  
Ultimately the goal of the screen is to identify 
molecular scaffolds which have affinity and selectivity to the poly(CUG) minor groove such that 
it can be combined with known targeting motifs. 
 
 
Figure 14.  Glycerol bound in minor groove of CUG4 
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 The glycerol-based in silico screen resulted in 117 molecules being identified as potential 
binders of trinucleotide repeat CUG.  Gel shift assays were performed with these identified 
molecules to determine their inhibitory activity.  The preliminary screening experiment utilized a 
CUG4 RNA construct to avoid time-consuming assay optimization.  From the 117 molecules, 12 
hits were identified based on greater than 5% displacement of CUG4 in comparison to the DMSO 
control. (Figure 15)  Most of the compounds identified only displaced 6-7% of RNA with Marvel 
4796 being the most active at 10% displacement.  There were concerns about the validity of 
CUG4 as a model for poly(CUG)n because it only has two U-U mismatches upon folding and 
might not contain enough bases to resemble A-form RNA which is formed by poly(CUG)n.  In 
addition, there were concerns that the UUCG motif in CUG4 construct may alter MNBL1 
binding to CUG.
13
  Thus, the screen was repeated with a CUG12 RNA construct.  
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Chembridge 5484017 Chembridge 6185525 Marvel 1174 
 
  
Marvel 1264 Marvel 4742 Marvel 4796 
   
Marvel 531 NSC 71426 NSC 143019 
  
 
NSC 194250 NSC 2561 NSC 287050 
Figure 15.  Hit compounds identified with CUG4 construct 
 
With 6 U-U mismatches upon folding and lacking the UUCG cap motif, CUG12 is a 
better model of toxic RNA than CUG4.  However, assay optimization was much more time-
consuming.  The screen resulted in identification of 13 lead compounds following the same 
guidelines as the CUG4 screen. (Figure 16)  Ligand 1, the positive control displaced an average 
of 23% relative to the RNA-protein complex while most identified hits averaged 8%. (Figure 17) 
Surprisingly, none of the compounds were identical from the two screens.  This suggested that 
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the CUG4 and CUG12 constructs may not form the same helical RNA structure in solution 
because completely different hits were identified.  Because we believed the CUG12 construct to 
better represent poly(CUG)n, we used the 13 hit molecules from the second screen for future 
analysis.   
 
 
  
Chembridge 5367911 Chembridge 5918715 Chembridge 6659423 
 
  
Chembridge 7490819 Marvel 4761 Marvel 4757 
  
 
HTSF 903 NSC 371679 NSC 403459 
  
 
NSC 403510 NSC 403958 NSC 371094 
 
  
NSC 380247   
Figure 16.  Hit compounds identified with CUG12 
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Figure 17.  Representative inhibition screening experiment 
(Top) gel image with hi compound boxed (Bottom) Densitometry data with hit shown in red 
 
 
Dose-dependent experiments with the 13 small molecules were inconclusive.  We 
observed that experimental data was highly variable between trials and high small molecule 
concentrations were required to observe significant inhibition.  Eventually it was realized that the 
sample binding buffer required for gel shift assay affected the results of the study.  Glycerol is a 
density increasing agent for gel shift samples and it is required for the experiment.  Because our 
initial pharmacophore model is based on glycerol binding in the minor groove, additional 
glycerol in the buffer blocks the intended target site.  Experimental protocols describe the use of 
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1.5 M glycerol per sample and steady-state fluorescence titration measurements with glycerol 
and TAMRA-CUG6 performed by a coworker showed a Kd of 1 M for glycerol with the RNA.  In 
other words, greater than half of the potential binding sites on CUG12 are occupied by glycerol in 
the gel shift assay.  The assay would be biased towards identifying compounds not sharing the 
same binding mode as glycerol.  There are alternative density-increasing agents one can use but 
to address this problem a fluorescence-based assay was developed and will be described in 
chapter 3. 
 
2.3 Conclusions 
 Through methodical improvements of assay conditions and sample buffer, a gel shift 
assay was developed into a more precise experiment for determining small molecule inhibition 
of MBNL1N-poly(CUG) binding.  Improvements allowed the direct comparison of ligand 1 
derivatives which was used in understanding the binding mode of the compounds as well as 
obtaining dose-dependent data for second generation compounds. Identification of ligand 12 as a 
strong inhibitor of RNA-protein interactions validated the rational design approach.  Screening 
experiments used to evaluate the glycerol-based pharmacophore model identified several 
compounds with observable inhibitor activity.  However, due to the necessity of glycerol as a 
density-increasing agent for the assay, the data obtained are inconclusive.  This experience 
served as motivation for the development of an orthogonal fluorescence-based method for 
determining small molecule inhibition.     
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2.4 Materials and Methods  
 
Plasmid 
 The expression vector pGEX-6p-1/MBNL1N (272 amino acids) was obtained from 
Maurice S. Swanson.
2
 MBNL1N has the four zinc finger motifs of MBNL1 and also a GST-tag 
at its N-terminal and a His6-tag at its C-terminal for purification.   
 
MBNL1N Expression and Purification 
 Bl21 E. coli cells were transformed with the GST-MBNL1N plasmid.  A mixture of 50 μl 
of cell, 1 μL of plasmid, and 0.7 μL of 10% BME was kept on ice for 20 min and then heat 
shocked for 45–55 sec at 42 °C.  After returning to ice for 30 sec, 450 μL of SOC media was 
added at room temperature.  The mixture was incubated in a shaker at 37 °C for 1 h. and then 
plated on agar and placed in a convection oven at 37 °C overnight for bacterial growth. 
 Transformed bacteria were induced with IPTG, once the OD600 reached 0.6, for 2 h at 37 
°C.  The solution was centrifuged for 15 min at 10,000 g and the pellet was saved and treated 
with lysis buffer (tris-Cl pH 8, 10 mM imidazole, 2mg/mL lysozyme, 0.1% Triton X, 0.1% 
protease inhibitor, 0.5 M NaCl, 2 mM BME, 5%glycerol).  Additionally, DNAse 1 was added to 
the lysate in a ratio of 1 μL of DNAse to 1 mL of lysis buffer.  After 6 rounds of sonication at 30 
sec each followed by 20 sec ice bath, the sample was centrifuged at 12,000 g for 15 min.  The 
supernatant was filtered with a 0.45 μM Millex Filter (Millipore).  One mL of Ni NTA 
Sepharose (QIAGEN) was added and incubated with lysate for 1 h at 4 °C.  The supernatant was 
removed and the beads are washed with 30 mL of wash buffer 1 (25 mM tris-Cl pH 8, 20 mM 
imidazole, 0.5 M NaCl, 0.1% Triton X).  The protein was eluted with 20 mL of elution buffer 
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(25 mM tris-Cl pH 8, 250 mM imidazole, 0.5 M NaCl, 0.1% Triton X water).  One mL of 
Glutathione Sepharose 4B (GE Healthcare) was incubated with the eluent for 1 h at 4 °C.  The 
solution was loaded on a column and the beads were washed with 20 mL of wash buffer 2 (25 
mM tris-Cl pH 8, 5 mM BME, 300 mM NaCl, 0.1% Triton X).  The column was sealed and the 
beads were suspended in 3 mL of wash buffer 2.  To the suspension, 5 mM of fresh BME and 40 
units of Precission Protease (GE Healthcare) were added.  This solution was kept at 4 °C with 
constant shaking for 48 h.  The suspension was centrifuged at 12,000 g and the supernatant was 
collected.   The solution was loaded into a column with Q Sepharose Fast Flow resin (Sigma-
Aldrich) and the protein was eluted with a gradient salt buffer (high salt buffer: 500 mM NaCl, 
25 mM tris-Cl pH 7.5, 5 mM BME; low salt buffer: 100 mM NaCl, 25 mM tris-Cl pH 7.5, 5 mM 
BME).  The concentration of protein obtained was determined with a BCA assay (Thermo 
Scientific) while purity was confirmed with MALDI mass spectrometry and SDS-PAGE. 
 
RNA Purification 
 (CUG)4 and (CUG)12 were purchased from Integrated DNA Technologies.  (CUG)4 was 
not purified while (CUG)12 was purified by performing a denaturing polyacrylamide gel 
electrophoresis with 12% polyacrylamide (National Diagnostics).  The gel was pre-run for 30 
min at 50 W prior to loading the RNA sample.  The RNA sample is mixed 1:1 with formamide 
buffer (95% fomamide, 10 mM tris-Cl pH 8, 20 mM EDTA, 100 µM bromophenol blue, 100 µM 
xylene cyanol).  Before loading, the sample is heat shocked for 2 min at 90 ⁰C.  The experiment 
is performed at 4 ⁰C with the power at 50 W until the dye has migrated to the bottom quarter of 
the polyacrylamide gel.  Afterwards the gel is removed from the glass plates, observed with UV 
lamp to mark the RNA region, and that portion is removed with a sterile razor.  The gel fragment 
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is forced through a syringe and 3 mL of 1X TE buffer is added for every 0.5 mL of gel fragment 
collected.  The tube is frozen at -80 ⁰C for 30 min, thawed at 50 ⁰C for 5 min, and soaked at 90 
⁰C for 5 min.  It is left on a shaker overnight.  The sample is extracted with n-butanol with the 
upper butanol layer removed after gentle shaking.  Two rounds of ethanol precipitation followed.  
For every 100 µL of sample solution, 30 uL of 3 M NaCl solution was added as well as 3 
volumes of cold ethanol.  The sample is left in dry ice for 30 min before centrifuged at 13,200 
rpm for 30 min at 4 ⁰C.  Afterwards ethanol was removed at reduced pressure and G-25 
Microspin (GE Healthcare) was used for buffer exchange into water.  RNA concentration was 
determined on Shimadzu UV2450 by measuring the absorbance at 260 nm.          
 
RNA Radiolabeling  
 (CUG)4 and(CUG)12 were labeled with 50 uCi [γ-
32
P] ATP with T4 Kinase (Invitrogen).  
The RNA was heat shocked for 5 min at 90 ⁰C prior to the experiment.  The reaction mixture, 
RNA, ATP, kinase and buffer, was placed in a water bath at 37 °C for 2 h and then moved to 
heat block of 70 °C for 30 min.  Chloroform/phenol extraction was performed by diluting the 
sample to 50 µL with water followed by addition of 50 µL of 25:24:1 phenol/chloroform/isoamyl 
alcohol.  After vortex and centrifuge the lower organic layer is removed.  A second extraction 
with 50 µL of 24:1 chloroform/ethanol is added and after vortex and centrifuge, the bottom 
organic layer is again removed.  Ethanol precipitation is performed twice following 
chloroform/phenol extraction.  The resulting solid is diluted with water and stored at -20⁰ C. 
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Equilibrium Binding Assay  
 The RNA was placed in 150 mL of near-boiling water and both left on the bench to 
return to room temperature for 90 min.  Next, the RNA samples were diluted with protein 
binding buffer (175 mM NaCl, 5 mM MgCl2 20 mM tris-Cl pH 8, 1.25 mM BME, 12.5% 
glycerol, 2 mg/mL BSA, 0.1 mg/mL heparin, and 0.05% Triton-X) to 0.4 nM.  The protein was 
serially diluted with protein binding buffer as well.  The two were mixed and incubated at room 
temperature for 20 min.  They were then loaded onto pre-chilled 4 °C 6% acrylamide gels in 
0.5X tris-borate buffer pH 8.2.  The gel was electrophoresised at 180 V for 1 h and then dried 
and visualized on a Molecular Dynamics Storm Phosphorimager.  Apparent Kd was obtained by 
fitting to the equation fraction RNA bound = 1/(1 + Kd / [Protein]) using KaleidaGraph 3.5. 
 
Inhibition Screening Assay 
 The RNA was prepared in the same fashion as the equilibrium binding assay.  The 
protein concentration used is the 80% bound state relative to the Kd.  Loading volumes were 10 
μL with 4.5 μL of RNA, 4.5 μL of protein, and 1 μL of small molecule.  The small molecule and 
protein were mixed initially, incubated for 20 min and then the RNA was added followed by 20 
min incubation time.  The gels were electrophoresised at 180 V for 1 h, dried, and visualized 
with phosphor imager.  Inhibition was determined by densitometry of free to complexed RNA. 
 
IC50 Assay 
 Small molecules were serially diluted from 10 mM and incubated with RNA for 20 min.  
MBNL1 was added and an incubated for an additional 20 min loading volume of 10 μL was used.  
The gels were electrophoresised at 180 V for 1 h and then dried and visualized.  To determine 
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IC50 values the data was fit to the equation B = ΔB exp((-0.69/IC50)C) + Bf where B is the 
volume of the free RNA and ΔB is the difference in the volume of the free RNA band at the 
lowest and highest concentrations of small molecule, C is the concentration of the small 
molecule, and IC50 is the concentration of small molecule at which 50% of the RNA is 
dissociated from the protein.   
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CHAPTER 3 
FLUORESCENCE ANISOTROPY FOR IDENTIFICATION OF 
LEAD COMPOUNDS 
 
3.1 Introduction 
 In 2006 Shapiro and coworkers described the use of fluorescence anisotropy for small 
molecule discovery for the vigilin-vitellogenin mRNA complex.
1
 The paper demonstrated the 
feasibility of using anisotropy in a high-throughput format for screening small molecule 
inhibitors of RNA-protein complexes.  However, no such assay has been published for the 
MBNL1-poly(CUG) system.  Compared to EMSA, anisotropy is much less time-consuming and 
laborious, it is an equilibrium-based measurement, and most importantly can be performed in a 
high-throughput methodology.  Furthermore, a fluorescence anisotropy assay could address the 
two inherent limitations of the gel shift assay 1) the requirement of a solid gel matrix for sample 
separation which prevents certain small molecules from being analyzed and 2) the necessity of 
using glycerol in the sample buffer.  This would allow us to complete the identification of lead 
molecules from the pharmacophore screen and allow for the design of a high-throughput screen.   
 
3.2 Results and Discussion 
Experimental Design 
 Fluorescence anisotropy measures the loss of polarization of the light emitted from the 
fluorophore, which is affected by the rate of tumbling of the bound complex.  Thus, to obtain the 
best signal difference between bound and free states, one needs the bound state to be much larger 
than the unbound, which minimizes the tumbling rate. (Figure 18)  The RNA construct used for 
the experiments is TAMRA-CUG6 (excitation 546 emission 579), which is attached to the 5’-end.  
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(Figure 19)  TAMRA was chosen as the fluorophore for its longer wavelength of excitation and 
emission that does not overlap with that that of ligand 1, its derivatives and most small molecules.  
Instead of using MBNL1N, 30 kDa, the larger GST-MBNL1N, 56 kDa, was selected.  The 
anisotropy buffer utilized was based on protocols from an AlphaScreen assay developed by 
Thornton and coworkers.
2
  However, BSA and Triton-X100 were supplemented to disrupt 
potential nonspecific small molecule and protein interactions.   
 
Figure 18.  Schematic of fluorescence anisotropy 
 
 
Figure 19. RNA construct (Left) CUG6 construct (Right) Structure of TAMRA fluorophore 
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Development of Assay Conditions and Protocols 
 Although the TAMRA-CUG6 was easily obtained through commercial sources, GST-
MBNL1N was difficult to purify and store.  Previously established protocols for expression of 
MBNL1N, transcribed from the GST-MBNL1N plasmid, utilizes Precision Protease (Amersham) 
to cleave the GST-tag after affinity chromatography with glutathione resin. Elimination of the 
protease step to preserve the GST tag reduced the purity of the collected protein. (Figure 20a)  
MBNL1N and GST is believed to be the major contaminants in the fraction based on SDS PAGE 
analysis.  To increase purity, cell lysate sonication time was reduced and affinity 
chromotography protocols were altered in comparison to MBNL1N expression to prevent self-
cleavage of GST-MBNL1N.  Excessive sonication time is known to cause cleavage of GST from 
fusion proteins.
3  
Improved purity of GST-MBNL1N was observed in SDS-PAGE (Figure 20b) 
and indirectly from stronger binding for GST-MBNL1N and CUG6 from fluorescence anisotropy 
experiments.   
 
Figure 20.  SDS PAGE of collected protein 
(a) protein prior to additional purification steps (b) protein post purification 
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After purification and concentration of GST-MBNL1N fractions, it was observed that 
protein precipitation had occurred.  It is known that GST-tagged proteins form dimers and 
tetramers and that such association is dependent on concentration.  For our purposes we needed 
the protein sample to be stored at high concentrations to avoid diluting assay buffer conditions.  
To prevent precipitation, we incorporated protein dialysis into the purification procedure, 
increased the amount of glycerol in the storage buffer, and maintained the concentration of the 
protein below 10 µM.  Even with these changes we observed protein precipitation over a period 
of four weeks.  Thus, it was decided that GST-MBNL1N be expressed fresh prior to fluorescence 
anisotropy experiments and screens.     
 At the completion of these optimization steps we began to test the validity of the assay by 
performing equilibrium binding assays with GST-MBNL1N and Tamra-CUG6 as well as 
inhibition assays with ligand 1 and comparing to published data.  Compared to the Kd values 
obtained with gel shift assays, the Kd values from anisotropy assays were about ten folds higher 
at 100 nM.  It is difficult to determine whether this resulted from different RNA construct or 
from the difference in assay.  For measuring Kd, fluorescence anisotropy data is much more 
variable than gel shift assays due to the slow degradation of GST-MBNL1N in solution over 
time.         
 Ligand 1 was chosen to be the control compound for inhibition studies because its IC50 
and Ki data is already published by Zimmerman and coworkers.
4  
Due to the slowly changing 
concentration of the GST-MBNL1N stock solution, a Kd was determined prior to each inhibition 
assay to determine the amount of GST-MBNL1N to use.  After three independent experiments 
we found that based on the anisotropy data the IC50 for ligand 1 is 87 ± 25 µM, from which a Ki 
value of 7 ± 2 µM is calculated.  This is similar to the published Ki of  7 ± 1 µM for ligand 1 from 
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gel shift assays. (Figure 21)  This result demonstrated that fluorescence anisotropy is a valid 
assay to determine small molecule inhibition of poly(CUG)-MBNL1 interactions.    
 
Figure 21.  Fluoresence anisotropy data for ligand 1 
         
   Prior to re-screening the 117 compounds selected from the in silico screen, it was 
necessary to determine the appropriate conditions with the assay performed in a high-throughput 
format.  Several factors needed to be addressed such as the order of addition and the incubation 
time for the small molecule with the RNA-protein complex. 
 Sample screening experiments were performed to determine the order of addition for the 
high-throughput screen, with the goal of minimizing addition steps.  For small molecule 
inhibition studies there are two typical methods of addition; prevention mode where the RNA-
small molecule is pre-incubated and protein is added later, and displacement mode where RNA-
protein is pre-incubated with small molecules added to displace the complex.  For gel shift 
experiments, prevention mode was employed because it resulted in better inhibitory response.  
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However, displacement mode requires one less compound addition step.  In addition to reducing 
addition steps, displacement mode will reduce the potential for bubbling in the wells due to the 
presence of Triton-X.  Triton-X is a detergent that is necessary to reduce small molecule 
aggregation but bubbles during any sample addition, leading to false fluorescence readings.  
From test screens we observed little difference in signal between the two methods of addition; 
thus, the displacement method was used.    
 The last factor addressed was the incubation time for the TAMRA-CUG6, GST-
MBNL1N and the small molecule.  Time was an important factor for the folding of TAMRA-
CUG6 most likely due to a competition between duplex and stem-loop formation but it was not 
known whether assay response would change over time.  Fluorescence anisotropy is an 
equilibrium assay so it is expected that response should not vary.  We compared test screens 
measure at 20 minutes, 40 minutes and 1 hour and found that inhibitory responses did not change.  
One hour was selected as incubation time to reduce bubble formation.   
Identification of Lead Molecules from the Pharmacophore Screen   
 The screening of 117 compounds was carried out in a high-throughput manner in under 6 
hours; including compound picking.  Ligand 4 was used as a control and demonstrated a 47% 
signal change compared to DMSO control lanes.  Overall, 18 compounds were identified as hits 
in the screen by demonstrating a greater than 10% signal change relative to the control (Figure 
22). Of the 18 compounds identified, 3 compounds were previously identified from the EMSA 
CUG12 screen, labeled with (12), and 3 compounds were previously identified from the EMSA 
CUG4 screen, labeled with (4).  The binding affinity of these compounds has been determined by 
Stacie Richardson and John Craffey and unfortunately the inhibition of MBNL1 is quite weak, 
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millimolar range.  A future project would be the derivatization of such scaffolds to increase 
inhibitory activity.   
 
 
  
Chembridge 5367911 (12) Chembridge 5457436 Chembridge 5571606 
  
 
Chembridge 5735170 Chembridge 5738653 Chembridge 5784159 
  
 
Chembridge 5836613 Chembridge 6595394 Chembridge 6659423 (12) 
  
 
Chembridge 7240162 Chembridge 7434823 Marvel 531 (4) 
 
  
Marvel 1312 Marvel 3884 Marvel 4742 (4) 
   
Marvel 4757 (12) Marvel 4796 (4) NSC 326654 
Figure 22.  Results from pharmacophore-based screen 
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High-throughput Screening of NCI Diversity Set III 
 Multiple lead compounds were identified from the in silico pharmacophore-based screen 
but most exhibited weak inhibitory activity.  To identify more effective lead compounds, we 
decided to explore an expanded molecular space through a high-throughput screen of the NCI 
Diversity Set III library that contains over a million pharmacophores.  This is possible because 
we have optimized the conditions of the fluorescence anisotropy assay for high-throughput 
screening.  Steps in the screening process include an initial high-throughput fluorescence 
anisotropy screen of the whole library; a gel shift confirmatory screen; and a third screen in the 
presence of t-RNA. (Figure 23) 
 
 
 
Figure 23.  Summary of screening process with number of compounds at each level listed 
 
 
 
NCI Repository: 140,000 
Diversity Set III: 1,597 
Anisotropy Screen: 14 
EMSA Screen: 
4 
tRNA 
Screen: 3 
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Small Molecule Library Selection 
 The small molecule library Diversity Set III from the National Cancer Institute (NCI) was 
chosen for the study because it was easily accessible, inexpensive, and designed to represent a 
maximum amount of pharmacophores.  From the 140,000 compounds stored at NCI, the 1,597 
compounds of Diversity Set III were selected based on 1) compound availability, 2) 
representation of novel pharmacophore, 3) structural rigidity, 4) pharmacologically desirable 
features, and 5) purity of compound.  The smaller size of the library is suitable for initial assay 
development.  Upon identification of a hit compound, the NCI freely provides up to 10 mg of 
any compound listed in the Diversity Set for additional studies, expediting the discovery process.  
Compared to commercial small molecule libraries, the cost of using the Diversity Set is greatly 
reduced.             
 
Screen Optimization and Results 
 Prior to screening the small molecule library the robustness of the assay was determined 
by calculating the Z-factor.
5
  Z-factor is a mathematical description of the separation between the 
positive and negative controls ranging from 1 (ideal separation) to 0 (overlapping values for the 
control).  A Z-factor of 0.5 to 1.0 is considered to be an excellent assay.  In figure 7, the y axis is 
the anisotropy value for each of the tested compounds which are on the x axis.  A total of 1,597 
compounds were tested.  In experiments with protein and RNA in buffer 0.178 ± 0.006 
anisotropy value was obtained; representing a fully bound state. (Figure 24 red bar)  In 
experiments with RNA only, representing a fully dissociated state, 0.121 ± 0.003 anisotropy 
value was obtained (Figure 24 green bar).  From these values, a Z-factor of 0.53 was calculated 
which means that the assay is considered to be robust. 
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Figure 24.  Plot of anisotropy data for all small molecules 
 
The high-throughput fluorescence anisotropy screen was performed at a small molecule 
concentration of 100 µM and resulted in the identification of 14 hits. Anisotropy is a measure of 
the loss of polarization of a fluorophore upon molecular rotation, thus larger complexes exhibit 
high anisotropy while smaller complexes exhibit low anisotropy.  Potential inhibitors are 
expected to decrease the anisotropy value in a fluorescence anisotropy assay because it is 
preventing the formation of the larger complex.  Compounds with anisotropy values below 0.14 
were selected for follow-up studies to confirm the results.  False positives are present in all high-
throughput assays.  These are shown as the data points that are outliers in figure 24.  In the 
fluorescence anisotropy assay, false positives mainly result from 1) aggregation-based inhibition 
and 2) direct quenching of the fluorophore through small molecule-fluorophore interactions.  To 
Z-factor: 0.53 
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address these issues the detergent Triton-X100 was used to reduce small molecule aggregation 
and a second confirmatory screen based on displacement of radio-labeled poly(CUG)12 RNA 
instead of fluorophore-based detection was employed.   
 From the 14 hits previously identified, only 4 compounds remained active. (Figure 25)  
Ligand 13 and a series of derivatives were previously described as an inhibitor of dihydrofolate 
reductase in 1994.
6 
 Several derivatives, such as ligand 14 were reported to show anti-cancer 
activity in mouse models. Ligand 15 is a doxorubicin derivative, which is a known DNA 
intercalator.
7
 Ligand 16, also known as gentian violet, is a dye used in Gram staining.  The same 
compound was identified as a hit molecule in a patent filed by Ohno and coworkers employing a 
high-throughput screen of biologically active compounds based on rescue of missplicing of cTnT 
in HEK293 cells.
8  
Ligand 17 and a series of bis-quaternary salts were also investigated as an 
anti-tumor agents in 1974.
9  
  
   
 
  
Ligand 13 Ligand 14 Ligand 15 
  
Ligand 16 Ligand 17 
Figure 25. Ligands identified through screening and confirmed with gel shift 
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 A third screen was employed to eliminate nonselective compounds by the addition of 
competitor tRNA.  Increasing amounts of tRNA were included in gel shift assay at a ratio of 
1500:1 and 5000:1 tRNA to poly(CUG)12 RNA.  Under such conditions, ligand 16 displayed loss 
of inhibition and was eliminated from the study. Of the remaining four lead compounds, the 
current focus is with ligand 13 and its derivative 14 because of a simpler synthetic scheme.  
Compounds 15 and 17 will be investigated in future work.   
 
SAR with Similar Compounds 
 A structure-activity-relationship experiment was employed to understand the molecular 
motifs important for inhibition.  Compounds similar to 13 defined by the Tanimoto similarity 
index were obtained from the NCI small molecule repository.  The Tanimoto similarity index 
uses atom connectivity to determine compound similarity with values ranging from 1 being 
identical to 0 being completely dissimilar.  Seventeen compounds were obtained from NCI with 
a similarity index higher than 0.9 but only one was a direct derivative of the compound 13, 
compound 14. (Figure 26)   The goal of the experiment is to determine what structural motif of 
13 is required for inhibition.  Surprisingly, only 13, (P = 0.002) and 14 (P = 0.03) demonstrated 
significant inhibition compared to the DMSO control whereas the other similar compounds did 
not exhibit significant activity (Figure 27). Compound 4 is the positive control and is one of the 
methylated derivatives of triaminotriazine-acridine conjugate.  Interestingly, the hydrogen 
bonding motif of ligand 13 is similar to hydrogen bonding formed by triaminotriazine. (Figure 
28)      The presence of the donor acceptor donor acceptor (DADA) hydrogen bonding motif 
formed by the two amines on the pyrimidine present in 13 and 14 may be necessary for activity. 
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Compared to the parent compound, 14 demonstrated increased inhibition (P = 0.015) suggesting 
additional derivatization at the indole nitrogen may lead to improved inhibition activity.  
 
 
 
  
Parent NSC 339578 (13) NSC 67064 NSC 27616 
 
 
 
NSC 78700 NSC 106570 NSC 115765 
   
NSC 128737 NSC 162910 NSC 162911 
   
NSC 309401 (14) NSC 346525 NSC 346529 
 
  
NSC 353101 NSC 361684 NSC 361685 
  
 
NSC 361686 NSC 361687 NSC 625168 
Figure 26. Compounds similar to ligand 13 
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Figure 27. Summary of three independent SAR screening experiments  (SEM is shown) 
 
 
 
 
 
Figure 28. Comparison of h-bonding motif (Left) triaminotriazine (Right) compound 13 
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Dose Dependent Inhibition Activity of Ligand 13 
 Dose-dependence studies were completed with compound 13 via gel shift assay to 
establish a value for head-to-head comparisons against known small molecule inhibitors and 
future synthesized derivatives.  Compound 13 exhibited an IC50 of 61 ± 15 μM with a calculated 
Ki of 15 ± 3 μM. (Figure 29)  These values compare favorably to other small molecule inhibitors 
of DM1 such as pentamidine with an IC50 of 58 ± 5 μM and compound 4 with an IC50 48 ± 1 
μM.4,10  Dose dependence studies with 14 were inconclusive because of small molecule 
aggregation at high small molecule concentrations leading to an incomplete dose-dependence 
profile.  The solubility of 14 will need to be characterized prior to additional dose-dependence 
experiments.  The low micromolar IC50 suggests 13 is a promising scaffold for further 
derivatization but compound solubility must be considered in derivative design.   
 
 
 
Figure 29. Representative gel and densitometry data for 7 independent dose-dependence experiments 
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Synthesis of 13 
 The synthesis of 2,4-diaminopyrroloquinazoline, 13, was first described by Ledig and 
coworkers through a thermally-induced condensation of sodium dicyanamide and 5-
aminoindole.
11
  In 1994 Styles and coworkers reported an improved synthesis through the 
isolation of a cyano intermediate 7 followed by BF3∙OEt2 assisted cyclization. (Scheme 1)
12
  
Following this method intermediate 18 has been successfully synthesized in high yield.  
Synthesis of compound 13 and its derivatives is now the project of a new graduate student. 
 
 
Scheme 1.  Synthesis of ligand 13 
 
 
 
3.3 Conclusions 
 The fluorescence anisotropy assay was developed to provide another method to analyze 
the lead molecules identified from the in silico pharmacophore-based screen.  However, a 
general screen of the NCI Diversity Set III has been more successful in identifying strong 
inhibitors of poly(CUG)n-MBNL1 complex than the pharmacophore-based screen.  We can now 
take advantage of the high-throughput capabilities of the anisotropy assay to quickly identify 
multiple lead compounds and to expand our portfolio of small molecule inhibitors for myotonic 
dystrophy. 
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 In regards to the identified molecules, additional experimental data is required to 
demonstrate that the RNA is the target of the small molecule as opposed to the protein.  
Quantification methods such as ITC and RNA melting experiments will be necessary for 
demonstrating small molecule-RNA binding.  Additional biological assays, such as fluorescence 
microscopy to visualize the displacement of mislocalized MBNL, splicing assays to determine 
the effects on splicing, and in vivo toxicology studies will be critical in evaluating the potential 
of the lead compound to be developed further. 
 The identification of active inhibiters possessing activities comparable to published small 
molecule inhibitors has shown the robustness of the fluorescence anisotropy assay.  However, 
the success of all high-throughput screening experiments is limited by the choice of library.  The 
larger the library, the more chemical space explored with the expectation of discovering more 
effective inhibitors.  As a proof of concept experiment, the screening of Diversity Set III, a 
relatively small library, demonstrates the effectiveness of the method.  Thus, future screens can 
employ much larger small molecule libraries such as the one available at the Molecular Libraries 
Program at NIH with 300,000 compounds with the goal of identifying even more potent lead 
compounds.  
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3.4 Materials and Methods 
 
GST-MBNL1N Expression and Purification 
 Bl21 E. coli cells were transformed with the GST-MBNL1N plasmid.  A mixture of 50 μl 
of cell, 1 μL of plasmid, and 0.7 μL of 10% BME was kept on ice for 20 min and then heat 
shocked for 45–55 sec at 42 °C.  After returning to ice for 30 sec, 450 μL of SOC media was 
added at room temperature.  The mixture was incubated in shaker at 37 °C for 1 h. and then 
plated on agar and placed in a convection oven at 37 °C overnight for bacterial growth.  
 Transformed bacteria were induced with IPTG, once the OD600 reached 0.6, for 2 h at 37 
°C.  The solution was centrifuged for 15 min at 10,000 g and the pellet was saved and treated 
with lysis buffer (tris-Cl pH 8, 10 mM imidazole, 2mg/mL lysozyme, 0.1% Triton X, 0.1% 
protease inhibitor, 0.5 M NaCl, 2 mM BME, 5%glycerol).  Additionally, DNAse 1 was added to 
the lysate in a ratio of 1 μL of DNAse to 1 mL of lysis buffer.  After 6 rounds of sonication at 10 
sec each followed by 30 sec ice bath, the sample was centrifuged at 12,000 g for 15 min.  The 
supernatant was filtered with a 0.45 μM Millex Filter (Millipore). Two mL of Glutathione 
Sepharose 4B (GE Healthcare) was incubated with the lysate for 1 h at 4 °C.  The solution was 
loaded on a column and the beads were washed with 1) 25 mL of wash buffer A (25 mM tris-Cl 
pH 8, 5 mM BME, 1 M NaCl, 0.1% Triton X), 2) 15 mL of wash buffer B (25 mM tris-Cl pH 8, 
5 mM BME, 300 mM NaCl, 0.1% Triton X), 3) 10 mL of wash buffer C (25 mM tris-Cl pH 8, 5 
mM BME, 150 mM NaCl, 0.1% Triton X), and eluted with 20 of Elution Buffer 2 (50 mL of 
wash buffer C, 10 mM reduced glutathione).  Two mL of Ni NTA Sepharose (QIAGEN) was 
added and incubated with lysate for 1 h at 4 °C.  The solution was loaded on a column and the 
beads were washed with 20 mL of Wash Buffer1 (25 mM tris-Cl pH 8, 20 mM imidazole, 0.1% 
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Triton-X, 0.5 M NaCl, 5 mM BME) and eluted with 20 mL of Elution Buffer 1 (25 mM tris-Cl 
pH 8, 250 mM imidazole, 0.1% Triton-X, 0.5 M NaCl, 5 mM BME).  The protein sample is 
dialyzed into storage buffer (100 mM NaCl, 25 mM tris-Cl pH 7.5, 5 mM BME, 25% glycerol) 
using molecular porous membrane tubing with molecular weight cutoff of 3.5 kDa (Spectra/Por) 
first for 1 hour and then overnight.   
 The concentration of protein obtained was determined with a BCA assay (Thermo 
Scientific) while purity was confirmed with MALDI mass spectrometry and SDS-PAGE. 
 
Fluorescence Anisotropy Equilibrium Binding Assay  
 The fluorophore is protected from light with aluminum foil during all steps.  TAMRA-
CUG6 was diluted with half the necessary amount of buffer with Anisotropy Folding Buffer (20 
mM tris-Cl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM BME, 0.05% Triton-X).  Next the 
sample is heat shocked at 90⁰ C for 5 min and then put on ice for 30 min.  Anisotropy Buffer (20 
mM tris-Cl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM BME, 0.05% Triton-X, 2 mg/mL BSA) 
is added to reach a final concentration of 40 nM. 
 The protein was serially diluted with anisotropy buffer.  The two were mixed and 
incubated at room temperature for 20 min before being transferred onto a 384-well plate 
(Greiner).  Fluorescence anisotropy readings were measured on an Analyst HT instrument using 
a beam splitter at 561 nm with excitation at 530±12.5 nm and emission at 570±5 nm.  Apparent 
Kd was obtained by graphing the change in anisotropy and fitting to the equation anisotropy = 
1/(1 + Kd / [Protein]) with KaleidaGraph 3.5. 
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Fluorescence Anisotropy Inhibition Screening Assay 
 The RNA was prepared in the same fashion as the fluorescence anisotropy equilibrium 
binding assay.  The protein concentration used is the 80% bound state relative to the Kd.  
Loading volumes were 10 μL with 4.5 μL of RNA, 4.5 μL of protein, and 1 μL of small molecule.  
The small molecule was first loaded onto the 384-well plate (Greiner) and a 20 min pre-
incubated mixture of TAMRA-CUG6 and GST-MBNL1N was added.  After an incubation of 1 h, 
fluorescence anisotropy readings were measured on an Analyst HT instrument using a beam 
splitter at 561 nm with excitation at 530±12.5 nm and emission at 570±5 nm. Inhibition was 
determined by comparing anisotropy change relative to DMSO control. 
 
Fluorescence Anisotropy IC50 Assay 
 The RNA was prepared in the same fashion as the fluorescence anisotropy equilibrium 
binding assay. Small molecules were serially diluted from 10 mM and loaded onto the 384-well 
plate (Greiner).  TAMRA-CUG6 and GST-MBNL1N were incubated for 20 min prior to addition 
onto plate.  After an additional 1 h incubation fluorescence anisotropy readings were measured 
on an Analyst HT instrument using a beam splitter at 561 nm with excitation at 530±12.5 nm and 
emission at 570±5 nm. To determine IC50 values the data was fit to the equation B = ΔB exp((-
0.69/IC50)C) + Bf where B is the relative anisotropy value and ΔB is the difference in the 
anisotropy value at the lowest and highest concentrations of small molecule, C is the 
concentration of the small molecule, and IC50 is the concentration of small molecule at which the 
relative anisotropy value is half the difference of the lowest and highest values. 
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High-throughput Anisotropy Screen 
 TAMRA-CUG6 was diluted with half the necessary amount of buffer with Anisotropy 
Folding Buffer (20 mM tris-Cl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM BME, 0.005% 
Triton-X).  Next the sample is heat shocked at 90⁰ C for 5 min followed by slow cooling over 30 
min to RT.  Anisotropy Buffer (20 mM Tris-Cl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM 
BME, 0.005% Triton-X, 2 mg/mL BSA) is added to reach a final concentration of 44.44 nM.  
GST-MBNL1N was diluted to 1.11 μM with anisotropy buffer.  The two were mixed and 
incubated at room temperature for 20 min before being transferred onto 5 384-well plates 
(Greiner) using Matrix Platemate (Thermo Sci.).  Each well was contained 9 μL of pre-incubated 
RNA and protein.  Pin transfer was used for the addition of 1 μL of 1 mM Diversity Set III stock 
to each well.  Fluorescence anisotropy readings were measured on an Analyst HT instrument 
using a beam splitter at 561 nm with excitation at 530±12.5 nm and emission at 570±5 nm. 
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